CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation

Treatment targeting CD19 by a chimeric antigen receptor expressed on T cells (anti-CD19 CAR-T) has led to a breakthrough in the management and treatment of relapsed and refractory B- cell acute lymphoblastic leukemia (B-ALL). After infusion, the efficacy of anti-CD19 CAR-T is monitored by bone marro...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Romera, Isabel, Galán-Gómez, Víctor, González-Martínez, Berta, Guerra García, Pilar, San Román Pacheco, Sonsoles, Corral Sánchez, Dolores, Mozo del Castillo, Yasmina, Bueno Sánchez, David, Sisinni, Luisa, González Guerrero, Alba, Castellano Dámaso, Serafin, Sánchez Zapardiel, Elena, Ruz Caracuel, Beatriz, Balas Pérez, Antonio, Pérez-Martínez, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393474/
https://www.ncbi.nlm.nih.gov/pubmed/36003375
http://dx.doi.org/10.3389/fimmu.2022.960412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393474/
https://www.ncbi.nlm.nih.gov/pubmed/36003375
http://dx.doi.org/10.3389/fimmu.2022.960412

Ejemplares similares